Xponance, Inc. Erasca, Inc. Transaction History
Xponance, Inc.
- $10.1 Billion
- Q1 2025
A detailed history of Xponance, Inc. transactions in Erasca, Inc. stock. As of the latest transaction made, Xponance, Inc. holds 13,116 shares of ERAS stock, worth $14,165. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,116
Previous 12,393
5.83%
Holding current value
$14,165
Previous $31,000
45.16%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ERAS
# of Institutions
162Shares Held
222MCall Options Held
20.6KPut Options Held
5.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.6MShares$24.4 Million1.95% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.3MShares$18.7 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$17.5 Million5.36% of portfolio
-
Logos Global Management LP San Francisco, CA13MShares$14 Million3.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$13.7 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $132M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...